These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 16846514)

  • 1. Gemcitabine in combination with EGF-Receptor antibody (Cetuximab) as a treatment of cholangiocarcinoma: a case report.
    Sprinzl MF; Schimanski CC; Moehler M; Schadmand-Fischer S; Galle PR; Kanzler S
    BMC Cancer; 2006 Jul; 6():190. PubMed ID: 16846514
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gemcitabine and oxaliplatin with or without cetuximab in advanced biliary-tract cancer (BINGO): a randomised, open-label, non-comparative phase 2 trial.
    Malka D; Cervera P; Foulon S; Trarbach T; de la Fouchardière C; Boucher E; Fartoux L; Faivre S; Blanc JF; Viret F; Assenat E; Seufferlein T; Herrmann T; Grenier J; Hammel P; Dollinger M; André T; Hahn P; Heinemann V; Rousseau V; Ducreux M; Pignon JP; Wendum D; Rosmorduc O; Greten TF;
    Lancet Oncol; 2014 Jul; 15(8):819-28. PubMed ID: 24852116
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Response to cetuximab and gemcitabine-oxaliplatin in an advanced case of intrahepatic cholangiocarcinoma.
    Bralet MP; Bellin MF; Guettier C; Adam R; Paule B
    Clin Oncol (R Coll Radiol); 2006 Jun; 18(5):426. PubMed ID: 16817335
    [No Abstract]   [Full Text] [Related]  

  • 4. Preliminary experience of cetuximab in the treatment of advanced-stage biliary tract cancer.
    Chang PY; Cheng MF; Lee HS; Hsieh CB; Yao NS
    Onkologie; 2010; 33(1-2):45-7. PubMed ID: 20164661
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination of gemcitabine and cetuximab in patients with advanced cholangiocarcinoma: a phase II study of the Belgian Group of Digestive Oncology.
    Borbath I; Ceratti A; Verslype C; Demols A; Delaunoit T; Laurent S; Deleporte A; Vergauwe P; Van Maanen A; Sempoux C; Van Cutsem E; Van Laethem JL;
    Ann Oncol; 2013 Nov; 24(11):2824-9. PubMed ID: 23975665
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cetuximab plus gemcitabine-oxaliplatin (GEMOX) in patients with refractory advanced intrahepatic cholangiocarcinomas.
    Paule B; Herelle MO; Rage E; Ducreux M; Adam R; Guettier C; Bralet MP
    Oncology; 2007; 72(1-2):105-10. PubMed ID: 18025804
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chemotherapy for inoperable advanced or metastatic cholangiocarcinoma: retrospective analysis of 78 cases in a single center over four years.
    Pracht M; Le Roux G; Sulpice L; Mesbah H; Manfredi S; Audrain O; Boudjema K; Raoul JL; Boucher E
    Chemotherapy; 2012; 58(2):134-41. PubMed ID: 22572213
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cetuximab, gemcitabine, and oxaliplatin in patients with unresectable advanced or metastatic biliary tract cancer: a phase 2 study.
    Gruenberger B; Schueller J; Heubrandtner U; Wrba F; Tamandl D; Kaczirek K; Roka R; Freimann-Pircher S; Gruenberger T
    Lancet Oncol; 2010 Dec; 11(12):1142-8. PubMed ID: 21071270
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I/IIa study of cetuximab with gemcitabine plus carboplatin in patients with chemotherapy-naive advanced non-small-cell lung cancer.
    Robert F; Blumenschein G; Herbst RS; Fossella FV; Tseng J; Saleh MN; Needle M
    J Clin Oncol; 2005 Dec; 23(36):9089-96. PubMed ID: 16301597
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination of HAI-FUDR and Systemic Gemcitabine and Cisplatin in Unresectable Cholangiocarcinoma: A Dose Finding Single Center Study.
    Pietge H; Sánchez-Velázquez P; Akhoundova D; Siebenhüner A; Winder T; Bachmann H; Nguyen-Kim TDL; Breitenstein S; Knuth A; Petrowsky H; Pestalozzi B; Clavien PA; Samaras P
    Oncology; 2021; 99(5):300-309. PubMed ID: 33657549
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Panitumumab in combination with gemcitabine and oxaliplatin does not prolong survival in wild-type KRAS advanced biliary tract cancer: A randomized phase 2 trial (Vecti-BIL study).
    Leone F; Marino D; Cereda S; Filippi R; Belli C; Spadi R; Nasti G; Montano M; Amatu A; Aprile G; Cagnazzo C; Fasola G; Siena S; Ciuffreda L; Reni M; Aglietta M
    Cancer; 2016 Feb; 122(4):574-81. PubMed ID: 26540314
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Delayed response to maintenance therapy after first-line chemotherapy in metastatic intrahepatic cholangiocarcinoma: a case report.
    Marciano R; Servetto A; Bianco C; Bianco R
    J Med Case Rep; 2017 Sep; 11(1):273. PubMed ID: 28946921
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase II trial of gemcitabine, irinotecan and panitumumab in advanced cholangiocarcinoma.
    Sohal DP; Mykulowycz K; Uehara T; Teitelbaum UR; Damjanov N; Giantonio BJ; Carberry M; Wissel P; Jacobs-Small M; O'Dwyer PJ; Sepulveda A; Sun W
    Ann Oncol; 2013 Dec; 24(12):3061-5. PubMed ID: 24146220
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cetuximab, gemcitabine and capecitabine in patients with inoperable biliary tract cancer: a phase 2 study.
    Rubovszky G; Láng I; Ganofszky E; Horváth Z; Juhos E; Nagy T; Szabó E; Szentirmay Z; Budai B; Hitre E
    Eur J Cancer; 2013 Dec; 49(18):3806-12. PubMed ID: 24007821
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Irinotecan Plus Gemcitabine and Fluorouracil in Advanced Biliary Tract Cancer: A Retrospective Study.
    Endlicher E; Schnoy E; Troppmann M; Rogler G; Messmann H; Klebl F; Gelbmann C; Kullmann F
    Digestion; 2016; 93(3):229-33. PubMed ID: 27089254
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: a multicenter phase II Trial.
    Xiong HQ; Rosenberg A; LoBuglio A; Schmidt W; Wolff RA; Deutsch J; Needle M; Abbruzzese JL
    J Clin Oncol; 2004 Jul; 22(13):2610-6. PubMed ID: 15226328
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [A Case of Liver Metastasis of Intrahepatic Cholangiocarcinoma That Achieved Clinical Complete Response after Gemcitabine and Cisplatin Combination Chemotherapy].
    Kim Y; Hata T; Tanizaki K; Okano M; Kawada J; Okuyama M; Yamasaki M; Murakami M; Shimizu J; Miwa H; Imamoto H; Tsujinaka T
    Gan To Kagaku Ryoho; 2019 Feb; 46(2):360-362. PubMed ID: 30914560
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Gemcitabine combined with capecitabine in the treatment for 41 patients with relapsed or metastatic biliary tract carcinoma].
    Yu ZY; Ouyang XN; Chen ZS; Li J; Chen X; Xie FW
    Zhonghua Zhong Liu Za Zhi; 2008 Feb; 30(2):144-6. PubMed ID: 18646701
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Resection of Advanced Intrahepatic Cholangiocarcinoma after an Effective Response to S-1 and Gemcitabine Combination Therapy].
    Kuga Y; Moriya T; Fukuda S; Nishida T
    Gan To Kagaku Ryoho; 2016 Jun; 43(6):773-5. PubMed ID: 27306819
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination chemotherapy with gemcitabine and cisplatin as first-line treatment for immunohistochemically proven cholangiocarcinoma.
    Lee GW; Kang JH; Kim HG; Lee JS; Lee JS; Jang JS
    Am J Clin Oncol; 2006 Apr; 29(2):127-31. PubMed ID: 16601429
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.